A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy

This study has been withdrawn prior to enrollment.

Sponsor:

Information provided by:

Millennium Pharmaceuticals, Inc.

ClinicalTrials.gov Identifier:

NCT00297921

First received: February 27, 2006

Last updated: June 4, 2008

Last verified: June 2008

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

Study Status:	This study has been withdrawn prior to enrollment.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given